🇺🇸 FDA
Pipeline program

Treatment of cancer with Immune Checkpoint Inhibition therapy boosted by High Intensity Focused Ultrasound Histotripsy (the iFOCUS study)

NL85300.041.23

Phase 1 other active

Quick answer

Treatment of cancer with Immune Checkpoint Inhibition therapy boosted by High Intensity Focused Ultrasound Histotripsy (the iFOCUS study) for Metastatic or unresectable solid malignancies. Standard of care treatment options must not be available or not be considered feasible. Patients must have a primary tumor or metastasis that is suitable for HIFU-HT treatment. is a Phase 1 program (other) at Disc Medicine with 1 ClinicalTrials.gov record(s).

Program details

Company
Disc Medicine
Indication
Metastatic or unresectable solid malignancies. Standard of care treatment options must not be available or not be considered feasible. Patients must have a primary tumor or metastasis that is suitable for HIFU-HT treatment.
Phase
Phase 1
Modality
other
Status
active

Clinical trials